You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The unbiased method minimizes tearing of cells and inserts circulating tumor cells and leukocytes into a custom cell culture medium for later downstream analysis.
The Seattle-based genomics technology firm said it intends to use the funds for working capital and general corporate purposes.
Natera claims that several Genosity products infringe its US Patent No. 10,732,220, titled "Methods for Simultaneous Amplification of Target Loci."
The company expects product and service revenue totaling $30.1 million, driven by higher instrument revenue, offset by declining consumables revenue.
The product uses spin columns to extract high molecular weight DNA with an average length of 100 kb or more from animal and bacterial cells.
The funding will help the San Francisco-based firm apply low-depth NGS as it builds diagnostic tests to aid therapy selection in more diverse populations.
The deals give 10x Genomics control of a combined 110 patents covering in situ analysis methods that the firm says will complement its existing platforms.
The two new grants add to a $1.5 million Phase II SBIR grant the company received from the National Institute of General Medical Sciences last year.
The Seattle-based firm has won two grants each worth $1.9 million to develop proximity ligation assays with applications in cytogenetics.
The newly CE-IVD-marked devices are part of the company's DNA/RNA Shield line of sample collection, preservation, and transportation products.
The firm's Nanotrap virus particles provide an alternative to RNA extraction kits and could help improve detection for respiratory viruses, including SARS-CoV-2.
The submission data highlights Parsortix's ability to harvest circulating tumor cells from metastatic breast cancer patient blood samples for downstream analysis.
Under the non-exclusive deal, Oxford Nanopore can include the technology, which targets long DNA fragments, in its nanopore sequencing products.
Illumina thinks the next-generation sequencing cancer testing market will grow to $75 billion over the next 15 years, driven by screening.
The company's technology uses CRISPR to deplete unwanted nucleic acid sequences from NGS libraries, leaving behind targets of interest.
Shares of Illumina fell in afternoon trading on the Nasdaq following a brief rise after the market open.
The Tokyo-based firm is looking to expand into the US market following a recent ¥700 million ($6.6 million) Series B financing round.
The agency is providing the material freely and asking for feedback, so it can fix possible problems before more widely disseminating it to labs and companies.
The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.
The single-cell genomics firm's agreements with multiple companies will cover Japan, South Korea, Taiwan, Australia, and New Zealand.
Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner.
Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.
A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.
In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.